Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26,434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network.
Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao DA, Weisman MH; Accelerating Medicines Partnership in RA/SLE Network; Petri M, Buyon J, Furie R. Izmirly PM, et al. Among authors: wu m. Arthritis Res Ther. 2024 Feb 20;26(1):54. doi: 10.1186/s13075-024-03275-z. Arthritis Res Ther. 2024. PMID: 38378664 Free PMC article.
Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.
Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabothu S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, Mokrzycki M, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium. Der E, et al. Among authors: wu m. Nat Immunol. 2019 Jul;20(7):915-927. doi: 10.1038/s41590-019-0386-1. Epub 2019 May 20. Nat Immunol. 2019. PMID: 31110316 Free PMC article.
Author Correction: Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.
Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabothu S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, Mokrzycki M, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium. Der E, et al. Among authors: wu m. Nat Immunol. 2019 Nov;20(11):1556. doi: 10.1038/s41590-019-0529-4. Nat Immunol. 2019. PMID: 31605099 Free PMC article.
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network.
Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH; Accelerating Medicines Partnership RA/SLE network; Petri MA, Buyon JP. Deonaraine KK, et al. Among authors: wu m. Lupus Sci Med. 2021 Aug;8(1):e000522. doi: 10.1136/lupus-2021-000522. Lupus Sci Med. 2021. PMID: 34389634 Free PMC article.
High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis.
Iwamoto T, Dorschner JM, Selvaraj S, Mezzano V, Jensen MA, Vsetecka D, Amin S, Makol A, Osborn T, Moder K, Chowdhary VR, Izmirly P, Belmont HM, Clancy RM, Buyon JP, Wu M, Loomis CA, Niewold TB. Iwamoto T, et al. Among authors: wu m. J Rheumatol. 2022 Apr;49(4):388-397. doi: 10.3899/jrheum.210391. Epub 2021 Nov 15. J Rheumatol. 2022. PMID: 34782453 Free PMC article.
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership.
Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, Apruzzese W, Belmont HM, Izmirly PM, Zaminski D, Wu M, Connery S, Payan-Schober F, Furie R, Dall'Era M, Cho K, Kamen D, Kalunian K, Anolik J, Barnas J, Ishimori M, Weisman MH; Accelerating Medicines Partnership (AMP) RA/SLE Network; Buyon JP, Petri M. Carlucci PM, et al. Among authors: wu m. Rheumatology (Oxford). 2022 Nov 2;61(11):4335-4343. doi: 10.1093/rheumatology/keac067. Rheumatology (Oxford). 2022. PMID: 35212719 Free PMC article.
Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network.
Carlucci PM, Preisinger K, Deonaraine KK, Zaminski D, Dall'Era M, Gold HT, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao D, Weisman MH; Accelerating Medicines Partnership in RA/SLE Network; Izmirly PM, Buyon J, Petri M. Carlucci PM, et al. Among authors: wu m. Rheumatology (Oxford). 2024 Mar 26:keae189. doi: 10.1093/rheumatology/keae189. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38530774
26,434 results
You have reached the last available page of results. Please see the User Guide for more information.